[{"address1": "Maxim 1", "address2": "2 Parklands Way Holytown", "city": "Motherwell", "zip": "ML1 4WR", "country": "United Kingdom", "phone": "44 14 1433 7557", "website": "https://tcbiopharm.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.", "fullTimeEmployees": 41, "companyOfficers": [{"maxAge": 1, "name": "Mr. Bryan Leland Kobel", "age": 44, "title": "CEO & Director", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 544560, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Martin Edward Thorp", "age": 71, "title": "CFO & Director", "yearBorn": 1952, "fiscalYear": 2023, "totalPay": 410521, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Camarra", "title": "Executive Vice President of Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lauren  Bor Ph.D.", "title": "Head of Commercial Development Division", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.71, "open": 0.72, "dayLow": 0.6818, "dayHigh": 0.7399, "regularMarketPreviousClose": 0.71, "regularMarketOpen": 0.72, "regularMarketDayLow": 0.6818, "regularMarketDayHigh": 0.7399, "beta": 0.249, "forwardPE": -0.15434782, "volume": 669733, "regularMarketVolume": 669733, "averageVolume": 1712165, "averageVolume10days": 3591340, "averageDailyVolume10Day": 3591340, "bid": 0.504, "ask": 0.901, "bidSize": 200, "askSize": 200, "marketCap": 5827587, "fiftyTwoWeekLow": 0.436, "fiftyTwoWeekHigh": 33.5, "fiftyDayAverage": 1.1192, "twoHundredDayAverage": 7.43498, "currency": "USD", "enterpriseValue": 59485428, "floatShares": 98445670, "sharesOutstanding": 8207870, "sharesShort": 38332, "sharesShortPriorMonth": 16525, "sharesShortPreviousMonthDate": 1728950400, "dateShortInterest": 1731628800, "sharesPercentSharesOut": 0.067, "heldPercentInsiders": 6.0000002e-05, "heldPercentInstitutions": 0.070149995, "shortRatio": 0.02, "shortPercentOfFloat": 0.0699, "impliedSharesOutstanding": 3195130, "bookValue": 26.108, "priceToBook": 0.02719473, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -8593896, "trailingEps": -291.0, "forwardEps": -4.6, "lastSplitFactor": "1:10", "lastSplitDate": 1722816000, "enterpriseToEbitda": -4.603, "52WeekChange": -0.9773163, "SandP52WeekChange": 0.25891924, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "TCBP", "underlyingSymbol": "TCBP", "shortName": "TC BioPharm (Holdings) plc", "longName": "TC Biopharm (Holdings) Plc", "firstTradeDateEpochUtc": 1644589800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "ef544858-646b-3e8d-bcb0-2aed3539a593", "messageBoardId": "finmb_1681274131", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.71, "targetHighPrice": 3.0, "targetLowPrice": 3.0, "targetMeanPrice": 3.0, "targetMedianPrice": 3.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 980955, "totalCashPerShare": 0.01, "ebitda": -12923699, "totalDebt": 1728127, "quickRatio": 0.459, "currentRatio": 0.882, "debtToEquity": 159.939, "returnOnAssets": -1.08915, "returnOnEquity": -12.1748, "freeCashflow": -6853025, "operatingCashflow": -10042216, "financialCurrency": "GBP", "trailingPegRatio": null, "__fetch_time": "2024-12-28"}]